IN2014MN01488A - - Google Patents
Info
- Publication number
- IN2014MN01488A IN2014MN01488A IN1488MUN2014A IN2014MN01488A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A IN 1488MUN2014 A IN1488MUN2014 A IN 1488MUN2014A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A
- Authority
- IN
- India
- Prior art keywords
- mixture
- subunits
- subunit
- mol
- relative
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 6
- 229920000642 polymer Polymers 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161580016P | 2011-12-23 | 2011-12-23 | |
| US201261639654P | 2012-04-27 | 2012-04-27 | |
| PCT/US2012/071477 WO2013096901A1 (en) | 2011-12-23 | 2012-12-21 | Pharmaceutical formulations for fumagillin derivative-phf conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01488A true IN2014MN01488A (https=) | 2015-04-17 |
Family
ID=48669583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1488MUN2014 IN2014MN01488A (https=) | 2011-12-23 | 2012-12-21 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20130189218A1 (https=) |
| EP (1) | EP2794582A1 (https=) |
| JP (1) | JP2015503635A (https=) |
| KR (1) | KR20140121827A (https=) |
| CN (1) | CN104024236A (https=) |
| IN (1) | IN2014MN01488A (https=) |
| TW (1) | TW201332574A (https=) |
| UY (1) | UY34542A (https=) |
| WO (1) | WO2013096901A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| EP3212668B1 (en) | 2014-10-31 | 2020-10-14 | AbbVie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| JP2018506509A (ja) | 2014-12-09 | 2018-03-08 | アッヴィ・インコーポレイテッド | 細胞透過性Bcl−xL阻害剤との抗体薬物コンジュゲート |
| KR20170093943A (ko) | 2014-12-09 | 2017-08-16 | 애브비 인코포레이티드 | 낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체 |
| EP3383910A1 (en) | 2015-11-30 | 2018-10-10 | AbbVie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
| AU2016365114A1 (en) | 2015-11-30 | 2018-05-17 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| EP3432925A4 (en) | 2016-03-22 | 2019-11-06 | Bionomics Limited | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY |
| RS61659B1 (sr) | 2016-05-17 | 2021-04-29 | Abbvie Biotherapeutics Inc | Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu |
| EP4094778B1 (en) | 2016-06-03 | 2024-05-15 | Novacyte Therapeutics Company.,LTD | Polymer linkers and their uses |
| JP2019521975A (ja) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | 抗egfr抗体薬物コンジュゲート |
| EP3469000A1 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| JP2019526529A (ja) | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | 抗b7−h3抗体及び抗体薬物コンジュゲート |
| BR112018075630A2 (pt) | 2016-06-08 | 2019-03-19 | Abbvie Inc. | anticorpos anti-cd98 e conjugados de fármaco de anticorpo |
| CN116173232A (zh) | 2016-06-08 | 2023-05-30 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
| EP3458479B1 (en) | 2016-06-08 | 2020-11-04 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| CN109563168A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
| BR112018075644A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anticorpos anti-cd98 e conjugados de anticorpo e fármaco |
| BR112018075639A2 (pt) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | conjugados de anticorpo fármaco anti-egfr |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| PL3817751T3 (pl) * | 2018-07-03 | 2025-09-08 | Fennec Pharmaceuticals, Inc. | Postacie użytkowe bezwodnego tiosiarczanu sodu |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| EP3972993A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
| AU2020327000A1 (en) | 2019-08-08 | 2022-03-31 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
| CN114786730A (zh) | 2019-11-05 | 2022-07-22 | 再生元制药公司 | N-端scFv多特异性结合分子 |
| AU2021205893A1 (en) | 2020-01-08 | 2022-06-23 | Synthis Therapeutics, Inc. | ALK5 inhibitor conjugates and uses thereof |
| EP4114860A1 (en) | 2020-03-06 | 2023-01-11 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| CN116249549A (zh) | 2020-03-27 | 2023-06-09 | 诺华股份有限公司 | 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| JP2024531915A (ja) | 2021-08-05 | 2024-09-03 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコmuc抗体およびその使用 |
| CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| CA3235106A1 (en) * | 2021-10-19 | 2023-04-27 | Sixiang FAN | Conjugate pharmaceutical preparation, preparation method therefor and use thereof______________ |
| EP4649092A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| CN121712526A (zh) | 2023-06-13 | 2026-03-20 | 辛瑟斯治疗股份有限公司 | 抗cd5抗体及其用途 |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| EP2217283A2 (en) * | 2007-11-28 | 2010-08-18 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| WO2010138719A1 (en) * | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
-
2012
- 2012-12-21 EP EP12858970.2A patent/EP2794582A1/en not_active Withdrawn
- 2012-12-21 CN CN201280063450.4A patent/CN104024236A/zh active Pending
- 2012-12-21 KR KR1020147020754A patent/KR20140121827A/ko not_active Withdrawn
- 2012-12-21 WO PCT/US2012/071477 patent/WO2013096901A1/en not_active Ceased
- 2012-12-21 US US13/725,900 patent/US20130189218A1/en not_active Abandoned
- 2012-12-21 UY UY0001034542A patent/UY34542A/es not_active Application Discontinuation
- 2012-12-21 JP JP2014548983A patent/JP2015503635A/ja active Pending
- 2012-12-21 TW TW101149115A patent/TW201332574A/zh unknown
- 2012-12-21 IN IN1488MUN2014 patent/IN2014MN01488A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140121827A (ko) | 2014-10-16 |
| UY34542A (es) | 2013-07-31 |
| CN104024236A (zh) | 2014-09-03 |
| TW201332574A (zh) | 2013-08-16 |
| WO2013096901A1 (en) | 2013-06-27 |
| WO2013096901A8 (en) | 2014-08-07 |
| EP2794582A1 (en) | 2014-10-29 |
| JP2015503635A (ja) | 2015-02-02 |
| US20130189218A1 (en) | 2013-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01488A (https=) | ||
| UA111820C2 (uk) | Модифікований зв'язуючий протеїн, що інгібує взаємодію vegf-а-рецептора | |
| MX347644B (es) | Macromoleculas estrella para el cuidado personal y del hogar. | |
| EP2812438A4 (en) | MANIPULATED STRAIN OF ESCHERICHIA COLI FOR THE PREPARATION OF POLY-R-3 HYDROXYALKONOATE POLYMERS WITH A DEFINED MONOMER COMPOSITION AND METHODS BASED ON IT | |
| MX2010009154A (es) | Moleculas conjugadas del factor viii. | |
| EP2621480A4 (en) | CATIONIC LIPIDS WITH LOW MOLECULAR WEIGHT FOR OLIGONUCLEOTIDE DELIVERY | |
| WO2012135025A3 (en) | Conjugated lipomers and uses thereof | |
| EP2635265A4 (en) | NOVEL CYCLIC AMINES OF LOW MOLECULAR WEIGHT WITH CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | |
| MX2013007537A (es) | Formulacion farmaceutica que comprende una droga biofarmaceutica. | |
| EA201200617A1 (ru) | Полимеры на основе циклодекстрина для доставки лекарственных средств | |
| EA201200122A1 (ru) | КОНЬЮГАТЫ ε-ПОЛИЛИЗИНА И ИХ ПРИМЕНЕНИЕ | |
| EP2555741A4 (en) | SPRAYABLE COMPOSITION COMPRISING A POLYMER FILLED WITH HIGH MOLECULAR WEIGHT | |
| BR112013028365A2 (pt) | "composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer". | |
| WO2011148177A3 (en) | Membrane enhanced polymer synthesis | |
| UA101497C2 (ru) | Конъюгаты фактора ix с увеличенным временем полужизни | |
| EP2557120A4 (en) | COMPOSITION FOR FORMING A HEAT-HARDENED FILM WITH LIGHTING ORIENTATION CHARACTERISTICS | |
| WO2013186632A3 (en) | Conjugates of biologically active molecules to functionalized polymers | |
| EA201270186A1 (ru) | Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений | |
| IN2014CN03735A (https=) | ||
| BR112012012486A2 (pt) | "combinação para o tratamento de mocosite induzida por radiação ou quimioterapia" | |
| IN2014DN07199A (https=) | ||
| BR112014004644A2 (pt) | polímeros funcionalizados com lactonas ou tiolactonas contendo um grupo amino protegido | |
| IN2014CN03509A (https=) | ||
| BRPI0923381A2 (pt) | polímeros redutores de atrito para aplicações de líquidos de baixo peso molecular | |
| MX2014008373A (es) | Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3. |